Clinical Trial Update: Efficacy and Safety Study of Bilateral IVT Injection of GS010 at Two Dose Levels in LHON Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating bilateral intravitreal injections of GS010 at two dose levels for Leber hereditary optic neuropathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Hereditary Optic Neuropathy

Drugs mentioned

• GS010 (lenadogene nolparvovec)

Snippet

Sponsor: GenSight Biologics | Conditions: Leber Hereditary Optic Disease | Phase 2 | Status: RECRUITING